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ABSTRACT
Type 2 diabetes results from a combination of insulin resistance
and impaired insulin secretion. To directly address the effects of
hepatic insulin resistance in adult animals, we developed an
inducible liver-specific IR knockout mouse (iLIRKO). Using this
approach, we were able to induce variable IR deletion in a tissue-
specific manner (liver mosaicism). These mice demonstrate
progressive hepatic and extra hepatic insulin resistance, without liver
dysfunction. Initially there is hyperinsulinemia and increased beta-
cell mass in parallel to IR deletion by the liver. Our results with
iLIRKO demonstrate a cause and effect relationship between
progressive insulin resistance and the fold-increase of plasma insulin
levels and beta-cell mass. Ultimately the beta cells undergo a failure
in the insulin secretion that leads to uncontrolled diabetes. In this
context, iLIRKO mice induced IGF-1 in parallel to IR (IR) deletion
in the liver. This resulted in an increase of circulating IGF-1.
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Concurrently, there was a huge increase of IR-A in the hyperplastic
beta cells. More importantly, as assessed in mouse beta-cell lines,
IR-A, but not IR-B, confers a proliferative capability to beta-cells
in response to insulin or IGF-1 that may account for beta-cell
hyperplasia induced by liver insulin resistance in iLIRKO mice. Thus,
our results in iLIRKO mice suggest a liver-pancreatic endocrine axis,
IGF-1 being a liver factor that might contribute together with insulin
to compensatory pancreatic islet hyperplasia through IR-A.
Keywords: Diabetes; IGF-1; Signalling; Mouse; Proliferation.
RESUMEN
Hiperplasia de célula beta inducida por resistencia hepática
a insulina: Papel de un eje hepato-pancreático
La diabetes tipo 2 es el resultado de una combinación de resis-
tencia a insulina y un defecto en la secreción de la misma. Para
determinar el papel de la resistencia a la insulina hepática en ani-
males adultos, nuestro grupo generó un ratón para el receptor de
insulina en hígado de forma inducible (iLIRKO). Utilizando esta
tecnología fuimos capaces de obtener ratones con distinto grado de
deleción del receptor de insulina hepático. Estos ratones mostraron
una resistencia progresiva a la insulina inicialmente hepática pero
que se extendió a tejidos extrahepáticos. Además, no se observó
ningún tipo de patología hepática. Inicialmente se observó un incre-
mento en los niveles de insulina circulantes y un aumento de la
masa de célula beta pancreática que fue proporcional al grado de
deleción del receptor de insulina en hígado. Finalmente, tiene lugar
un fallo en la secreción de insulina por parte de la célula beta pan-
creática. En este contexto, el hígado de los animales iLIRKO es
capaz de sintetizar IGF-1 de forma proporcional al grado de deleción
del receptor de insulina en hígado. Además, tuvo lugar un importan-
te incremento en la expresión de la isoforma A del receptor de insu-
lina (IR-A) en las células beta. Más importante, como demostramos
en células beta inmortalizadas, IR-A pero no IR-B confiere una gran
capacidad proliferativa a las células beta en respuesta tanto a in-
sulina como IGF-1, lo que puede explicar, al menos en parte, los
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mecanismos involucrados en la hiperplasia de la célula beta pan-
creática desarrollada por los ratones iLIRKO.
Palabras clave: Diabetes; IGF-1; Señalización; Ratón; Prolife-
ración.
1. INTRODUCTION
Type 2 diabetes results from a combination of insulin resistance
and impaired insulin secretion. While it is not clear the primary
defect in type 2 diabetes, insulin resistance is the most relevant
pathophysiological feature in the prediabetic state (1, 2). Rodent
studies have shown that insulin insensitivity in both classical and
non-classical insulin target tissues can play a role in the control of
glucose homeostasis (3). Several mouse models have been developed
to study the role of insulin resistance in various tissues (4). While
total whole body insulin resistance produced by generalized deletion
of the IR does not produce any major effect in mouse development,
these mice died one week after birth from severe ketosis (5, 6).
Combined restoration of IR function in brain, liver, and pancreatic
b cells rescues IR knockout mice from neonatal death, prevents
diabetes in a majority of animals, and normalizes adipose tissue
content, lifespan and reproductive function (7).
In a serie of studies using tissue-specific conditional knockout
of IR, the liver, brain and beta cell have also been implicated as the
key sites of insulin resistance in the development of type 2 diabetes
(8-10). The liver-specific IR knockout (LIRKO) showed that hepatic
insulin resistance is the most important in development of impaired
glucose tolerance and fasting hyperglycemia. In addition, these mice
also developed marked beta-cell hyperplasia and hyperinsulinemia
and decreased insulin clearance. With aging, however, the diabetic
state regressed, suggesting some form of compensatory mechanism,
possibly linked with the development of liver damage related to
appearance of hyperplastic nodules that might have altered glucose
production by the liver, leading to regression of the diabetic state
with aging (8). To better address the role of this important tissue in
the pathogenesis of type 2 diabetes in the adult, we developed LIRKO
mice in an inducible manner (iLIRKO).
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2. MATERIALS AND METHODS
2.1. Animals
IR(loxP/loxP) C57Bl/6 mice were created by homologous recombi-
nation using an IR gene targeting vector with lox P sites flanking exon
4 as previously described (11). Transgenic mice expressing a Cre
recombinase transgene under the control of the Mx1 promoter/
enhancer were purchased from Jackson Laboratory (Bar Harbour,
Maine, USA). The IR(loxP/loxP) mice were crossed with Mx-Cre mice to
obtain inducible LIRKO (iLIRKO) mice. After the suckling period,
iLIRKO mice were injected intraperitoneally with poly-Inositic-poly-
Cytidilic acid (500 mg/injection) to induce the interferon alpha
response and the consequent Mx1 promoter activation as previously
described (12). All animal experimentation described in this
manuscript was conducted according with accepted standards of
human animal care published by the National Institutes of Health.
2.2. Genotyping of the IR(loxP/loxP) transgenic mice
Genotyping of the mice was performed by PCR. Tail DNA (100-
200 ng) was amplified 30 cycles (40 seconds, 94° C; 40 seconds,
60° C; and 1 minute, 75° C) on a thermal cycler. Two primers
flanking the loxP site behind exon 4 of the IR were used: the forward
primer (5’-GATGTGCACCCCATGTCTG-3’) and the reverse primer (5’-
CTGAATAGCTGAGACCACAG-3’). A 320-bp band was obtained for
the floxed allele or a 280-bp band for the wild-type allele.
2.3. Genotyping of the Mx1-Cre transgenic mice
Mice were genotyped by PCR. Tail DNA (100-200 ng) was ampli-
fied 35 cycles (1 minute, 94° C; 1 minute, 60° C; and 1 minute, 72° C)
on a thermal cycler. To amplify the Mx1-Cre transgene (PCR product,
269 bp), primers SF-4 (5’-GCATAACCAGTGAAACAGCATTGCTG-3’)
and 69R (5’-GGACATGTTCAGGGATCGCCAGGCG-3’) were used.
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2.4. Western blot analysis
Tissues were homogenized as described (11). Western blot
analyses of insulin signaling proteins were performed as described
(13). The antibodies used were anti-IRβ (Ab-4) from Oncogene
(San Diego, CA), anti-PEPCK antibody was kindly provided by
Dr. DK. Granner (Vanderbilt University, TN), Anti-Glucokinase
antibody was a generous gift of Dr. S. Lenzen (Hannover Medical
School, Germany), anti-FAS antibody was purchased from BD
Transduction Laboratories (San Diego, CA) anti-β-actin antibody
was from Sigma-Aldrich Corp. (St. Louis, MO). Anti-IGF-1 antibody
was purchased from Upstate Biotechnology (Lake Placid, NY).
Anti-phospho-p70-S6-Kinase (Thr421/Ser424), anti-phospho-p44/
p42-MAPK (Thr202/Tyr204), anti-phospho-Akt (Ser473) antibodies
were purchased from Cell Signaling (Beverly, MA). For in vivo insulin
signaling studies, mice were intraperitoneally injected with 1 U/kg
body weight of human insulin (Novo Nordisk, Denmark). After 10
minutes, the tissues were removed and frozen in liquid nitrogen.
Densitometric analysis of the autoradiograms was performed using
a GS-710 Imaging Densitometer and the Quantity One software (Bio-
Rad Laboratories, CA).
2.5. Analytical procedures
Insulin levels in serum were measured by radioimmunoassay (RIA)
using mouse insulin as a standard (Linco Research, MO). IGF-1 levels
in serum were measured by RIA using mouse IGF-1 as a standard
(Diagnostic Systems Laboratories, TX). Glucose tolerance and insulin
tolerance tests were performed as previously described (14).
2.6. Histological analysis
The immunohistochemical analysis of pancreata was preformed
as described (14). β cell mass was evaluated by point counting
morphometry (15, 16). Staining of liver sections with hematoxylin/
eosin, periodic Acid-Schiff (PAS) and Masson reagents was
performed using standard techniques.
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2.7. Real-time quantitative PCR for IR isoforms
The pancreatic islets were isolated from 6-month-old control and
iLIRKO mice as previously described (10). IR isoforms expression in
isolated islets was analyzed by qPCR, using Taqman probes (Applied
Biosystems, NJ). The comparative threshold cycle (Ct) method was
used to calculate the relative expression. For gene expression
quantification, the target genes values were normalized to the
expression of the endogenous reference (18S). Thus, the amount of
target, normalized to 18S and relative to the control is given by 2-ΔΔCt
[ΔCt = Ct (Target gene) - Ct (18S); ΔΔCt = ΔCt for any sample - ΔCt
for the control].
2.8. Reconstitution of IRKO immortalized beta cells with
2.8. IR A or B iosoforms b retroviral infection
IRKO beta cells were generated in our laboratory as previously
described (17). From these cells we reconstituted and characterized
the expression of the IR-A (Rec A) and IR-B (Rec B) generating new
cell lines as previously described (18).
2.9. Measurement of glucose uptake in beta cells
Cells were cultured to 80% confluence in 10% FBS-DMEM and
then serum and glucose starved for 4-6 h. After that, 10 nM Insulin
or 10 nM IGF-1 were added to the wells for 30 min. Glucose uptake
was measured by incubating cells with 2-deoxy-D-[1-3H]glucose for
the last 10 min, in triplicate dishes from six independent experiments
as previously described (19).
2.10. Cell viability assays
Cells were plated in 12-multiwell plates and cultured in 10% FBS-
DMEM until 40-50% of confluence was reached. Then cells were
serum starved for 4 h, and then treated with 10nM Insulin, 10 nM
IGF-1 or both during 24 hours. Then, the cells were washed with
PBS and stained with violet crystal as described (17).
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2.11. Proliferation studies in isolated pancreatic islets
2.11. and cultured cells
DNA synthesis in isolated islets was estimated by determining
BrdU incorporation by using the Cell Proliferation ELISA kit (Roche
Diagnostics GmbH, Germany). In cultured beta cells the DNA syn-
thesis was estimated by [3H]-thymidine incorporation as previously
described (20).
2.12. Statistical analysis
All values are expressed as mean +/– SEM. Statistical analyses
were carried out using a two-tailed Student’s unpaired t test, and the
null hypothesis was rejected at the 0.05 level.
3. RESULTS
3.1. Progressive liver-specific IR deletion without liver
3.1. dysfunction
The iLIRKO mice were generated as described in Materials
and Methods. These mice showed variable IR deletion and were
grouped into three groups (50, 25 and 0% of the normal receptor
complement). Ablation of IR was tissue-specific, none of other tissues
studied were affected (Figure 1).
A critical issue in constitutive LIRKO was the appearance of some
liver dysfunction. However, hematoxylin-eosin staining in liver
sections revealed no dysplastic or hyperplastic nodules in 6 month-
and 12 month-old iLIRKO mice as compared with their respective
controls. In addition, Masson staining showed no increase in collagen
infiltration or fibrosis in iLIRKO mice (Figure 2, upper panels).
Regarding enzymes of hepatic glucose metabolism, we found two
kind of evidence as compared with constitutive LIRKO mice. Thus,
late IR deletion in iLIRKO mice resulted in reduced glucokinase
(GK) protein expression and a dramatic loss of glycogen liver
content, as shown by PAS-staining of liver sections, as previously
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reported in early insulin IR deletion (8). However, no effect was
observed on phosphoenol pyruvate carboxykinase (PEPCK) or fatty
acid synthase (FAS) gene expression in 6 month-old iLIRKO mice as
compared with controls (Figure 2, lower panels).
Figure 1. Induction of Liver-Specific IR Knockout. A) (Upper panel) Liver
protein extracts from 6-month-old Control and iLIRKO mice were analyzed by
Western blot. (Lower panel) The autoradiograms corresponding to four independent
experiments were quantitated by scanning densitometry. B) Protein extracts of
several tissues from 6-month-old Wt, IR(loxP/loxP) and iLIRKO mice were analyzed
by Western blot. A representative experiment out of four is shown. Results are
expressed as mean +/– SEM. **P < 0.005; *P < 0.05; iLIRKO vs. Control.
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3.2. Progressive insulin resistance and glucose intolerance
3.2. in inducible LIRKO
At 6 months of age iLIRKO mice demonstrated defects in insulin
signaling proportional to the lost of IR expression. Thus, in the group
with 50% of IR expression, there was a marked decreased in Akt,
ERKs and p70-S6-kinase activation while in the group with complete
IR deletion; there was a virtual absence of insulin activation of these
enzymes. Interestingly, despite the fact that there was no IR lost in
other tissues (Figure 1, panel B), there was a progressive impairment
of insulin signaling in other peripheral tissues. Thus, there was
progressive insulin impairment on Akt, ERKs and p70-S6-kinase
signaling from 50 to 0% IR expression left by the liver, in brain,
Figure 2. Liver Histology and Metabolic Gene Expression in iLIRKO mice.
A) Periodic Acid-Schiff reagent (PAS), Hematoxylin/Eosin and Masson staining of
liver sections from random-fed, 6-month- and 1-year-old male control (upper panel)
and iLIRKO (lower panel) mice. A representative experiment out of four is shown.
Magnification 20X. B) Protein liver extracts from 6-month-old Wt, IR(loxP/loxP) and
iLIRKO mice were analyzed by Western blot. A representative experiment out of
five is shown. Histograms show the densitometric analysis.
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skeletal muscle or brown adipose tissue (BAT) (Figure 3). Insulin
signaling in both the liver and these extra hepatic tissues was
similarly impaired in 1 year-old iLIRKO mice, (Figure 4). These
results indicate that iLIRKO mouse develops primary insulin
resistance in the liver, and this is associated with secondary insulin
resistance in extra hepatic tissues which persists throughout the
animal life.
Figure 3. iLIRKO Shows Insulin Resistance in the Liver and Extra Hepatic
Tissues. In vivo insulin signaling studies were performed in 6-month-old Control
and iLIRKO mice by intraperitoneal injection of 1 U/kg body weight of human
insulin. After 10 minutes, the tissues were removed and analyzed by Western blot.
A representative experiment out of four is shown. Histograms show the densitome-
tric analysis.
Post-weaning IR deletion induced progressive insulin resistance in
iLIRKO mice from 2- to 6-month-old and this persisted at 1 year of
age (Figure 5, upper panels). More importantly, the mice with no IR
expression showed progressive glucose intolerance, and even develo-
ped fasting hyperglycemia at 1 year of age (Figure 5, lower panels).
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3.3. Progressive beta-cell hyperplasia and failure of insulin
3.3. secretion with aging
iLIRKO showed progressive beta-cell hyperplasia as compar-
ed with controls. More importantly, the level of hyperplasia was co-
rrelated to the level of IR expression remaining in the liver (Figure 6,
panel B). The iLIRKO mice also developed progressive hyperinsuline-
mia as compared with controls and paralleled with the level of IR
deletion by the liver (Figure 6, panel B). This beta-cell expansion per-
sisted throughout life as shown in Figure 6, panel D. In parallel, plas-
Figure 4. Generalized Insulin Resistance persists in aged iLIRKO. In vivo
insulin signaling studies were performed in 1-year-old Control and iLIRKO mice by
intraperitoneal injection of 1 U/kg body weight of human insulin. After 10 minutes,
the tissues were removed and analyzed by Western blot. A representative experi-
ment out of four is shown. Histograms show the densitometric analysis.
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ma insulin increased by 2.5-fold in 1-year-old mice as compared with
their controls (Figure 6, panel D), however, this increase was much
lower than those at 6 months of age (3-fold, panel D), suggesting a
failure in insulin secretion with aging.
Figure 5. Progressive Insulin Resistance and Glucose Intolerance in iLIRKO
mice. A) Insulin tolerance tests were performed on random-fed, 2-, 4-, 6-month-
and 1-year-old male Control (white circles) and iLIRKO (black circles) mice. Animals
were injected intraperitoneally with 1 U/kg body weight of human insulin. Blood
glucose was measured immediately before injection and 15, 30, and 60 min after the
injection. Results expressed as percentage of initial blood glucose concentration are
means +/– SEM (n = 10-20). B) Glucose tolerance tests were performed on 2-, 4-, 6-
month- and 1-year-old Control (white circles) and iLIRKO (black circles) mice that
had been fasted for 16 h. Animals were injected intraperitoneally with 2 g/kg body
weight of glucose. Blood glucose was measured immediately before injection and
30, 60, 90 and 120 min after the injection. Results are expressed as mean +/– SEM
(n = 10–20). **P < 0.005; *P < 0.05; iLIRKO vs. Control.
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3.4. Progressive hepatic expression and plasma
3.4. concentration of IGF-1 in iLIRKO mice
Previous studies have suggested the presence of a circulating
islet growth factor in insulin resistant states, independent of glucose
and obesity (21). To address this important issue, we conducted
western blot analysis with anti-IGF-1 antibody in the liver. Thus,
iLIRKO induced expression depending on the level of IR deletion
by the liver (Figure 6, panel A). In parallel, iLIRKO mice induced
IGFBP1 and IGFBP3 also depending on the level of IR deletion
by the liver. These data were confirmed in 1 year-old mice (Figure
6, panel C). Noteworthy, iLIRKO mice bearing no liver IR expression
significantly induced plasma IGF-1 in 6 month- and 1 year-old mice
as compared with controls (Figure 6, panels B and D respectively).
3.5. Increase of IR-A in pancreatic islets: beta cell lines
3.5. expressing IR-A, but not IR-B, show increased
3.5. proliferation in response to insulin or IGF-1
The IR expression in pancreatic islets was significantly increased
in iLIRKO mice (Figure 7, panel A). More importantly, the percentage
of IR-A from total IR dramatically increased in these mice (Figure 7,
panel A). In order to investigate a possible role of this change in the
pattern of expression of the IR isoforms in the beta-cell hyperplasia,
we performed experiments of BrdU incorporation in pancreatic islets
of 6-month-old control and iLIRKO mice in presence of 10 nM insulin
or 10 nM IGF-1. The results showed that the islets of iLIRKO mice
were significantly more sensitive to the IGF-1-induced proliferation
than those control islets. Previous data indicated that IR-A was 2-fold
more sensitive than IR-B in response to insulin regarding glycogen
synthesis and also mitogenesis (22). To assess those results in mouse
beta cells, we have generated beta cell lines bearing IR (IRLoxP),
lacking IR (IRKO), expressing exclusively IR-A (Rec A), or alterna-
tively expressing IR-B (Rec B) (Figure 7, panel C). Moreover, the
generated cell lines were completely functional as assesed by IR and
IGF-1R phosphorylation experiments (Figure 7, panel D). The lack
of IR significantly decreased basal glucose uptake in beta cells.
Reconstitution with IR-A, but not with IR-B, restored basal glucose
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Figure 6. Progressive IGF-1 Liver Expression, Beta-Cell Hyperplasia and
Insulin Secretion Defect with Aging in iLIRKO. A) Liver extracts from 6-month-
old Control and iLIRKO mice with different IR deletion were analyzed by Western
blot. The autoradiograms of IGF-1 were quantified by scanning densitometry from
four independent experiments. B) (Upper panel) Beta cell mass was determined in
6-month-old Control (white bars) and iLIRKO mice with different grade of IR
deletion. Results were shown as fold increase of Control beta cell mass. Data shown
are from five independent experiments. (Lower-Left panel) Plasma insulin content
was measured in 6-month-old male Control (white bars) and iLIRKO mice with
different grade of IR deletion. Values are expressed as mean +/– SEM (n = 4).
(Lower-Right panel) Plasma IGF-1 content was measured in 6-month-old male
Control (white bars) and iLIRKO mice with different grade of IR deletion by RIA.
Values are expressed as mean +/– SEM (n = 4). C) Liver extracts from 1-year-old
Control and iLIRKO mice were analyzed by Western blot. A representative
experiment out of four is shown. D) (Upper panel) Beta cell mass was evaluated by
point counting morphometry in 1-year-old Control and iLIRKO mice. Results were
shown as fold increase of Control beta cell mass. (Lower-Left panel) Plasma insulin
content was measured in 1-year-old male Control and iLIRKO mice by RIA. Values
are expressed as mean ± SEM (n = 4). (Lower-Right panel) Plasma IGF-1 content was
measured in 1-year-old male Control and iLIRKO mice by RIA. Values are expressed
as mean ± SEM (n=4).*P < 0.05; **P < 0.005; ***P < 0.001 iLIRKO vs Control.
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uptake to levels higher than those observed in control cells (Figure 7,
panel E). In addition, insulin or IGF-1 enhanced cell viability
in control cells. In the same way, IGF-1 induced cell viability in
beta cells lacking IR. Rec A but not Rec B cells, increased cell viability
in response to either insulin or IGF-1 (Figure 7, panel F). More
importantly, insulin or IGF-1 increased proliferation, as estimated
by thymidine incorporation, in control beta cells. However, beta
cells lacking IR did not respond to IGF-1. Finally, insulin and
IGF-1 induced proliferation in Rec A but not in Rec B cells (Figure 7,
panel G).
4. DISCUSSION
Insulin promotes both metabolism and growth in the liver.
Constitutive ablation of IR in liver resulted in both metabolic changes
and a reduction in liver size by about 50% (8). Likewise, mice in
which there is variable IR deletion (cellular mosaicism) exhibit
different degrees of growth retardation and metabolic abnormalities
depending on the extent of IR deletion (23). Those findings suggest
that insulin regulates growth independently of metabolism and
that the IR number is an important determinant of the insulin
action specificity. Using the approach to generate LIRKO mice in
an inducible manner, we were able to induce variable IR deletion
(liver mosaicism). As a result, iLIRKO induced progressive insulin
resistance and glucose intolerance without growth retardation. Under
our experimental conditions, the insulin-induced effect on growth
and metabolic regulation are mutually independent. Thus, while
the late IR deletion gave rise to irreversible insulin resistance and
progressive glucose intolerance for over one year, no liver damage
was observed.
Previous tissue specific knockout and tissue specific reconstitution
studies concluded that the progression of insulin resistance to
diabetes with fasting hyperglycemia requires defects in tissues other
than liver (7, 8). More importantly, acute IR deletion by the liver
although impaired insulin signaling did not induce insulin resistance
or hyperinsulinemia (24). Our results show that liver-specific
disruption of IR could produce impaired hepatic and extra hepatic
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Figure 7. Increase of IR-A in pancreatic islets: Rec A but not Rec B cells show
increased proliferation in response to insulin or IGF-1. A) mRNA levels of IR
and the isoforms distribution were analyzed by qPCR in 6-month-old Control and
iLIRKO mice. Values are expressed as mean ± SEM (n = 4). *P < 0.05; **P < 0.005;
***P < 0.001 iLIRKO vs Control. B) Pancreatic islets proliferation was assesed by
BrdU incorporation in 6-month-old Control and iLIRKO mice. Values are expressed
as mean ± SEM (n = 4). *P < 0.05. C) IR expression was analyzed by Western Blot
and RT-PCR in IRLoxP, IRKO, Rec A and Rec B beta cells. A representative
experiment out of four is shown. D) Functional assessment of IR reconstitution
was carried out by phosphorylation experiments. E) Glucose uptake induced by
Insulin (vertical striped bars) or IGF-1 (horizontal striped bars) was measured in
each cell line. Statistical significance was carried out by Student’s t test by
comparison of IRKO and Rec A with IRLoxP beta cells respectively (*, P < 0.05).
F) Cell viability was measured in each cell line by violet crystal staining after a 24h
treatment with 10 nM Insulin (vertical striped bars), 10 nM IGF-1 (horizontal striped
bars) or both (black bars). Statistical significance was carried out by Student’s t test
by comparison of basal conditions with insulin-stimulated conditions of each cell
line (*, P < 0.05) or basal conditions with IGF-1-stimulated conditions of each
cell line (#, P < 0.05). G) Cell proliferation was measured in each cell line by
Thymidine incorporation after a 24h treatment with 10 nM Insulin (vertical striped
bars), 10 nM IGF-1 (horizontal striped bars) or both (black bars). Statistical
significance was carried out by Student’s t test by comparison of basal conditions
with insulin-stimulated conditions of each cell line (*, P < 0.05) or basal conditions
with IGF-1-stimulated conditions of each cell line (#, P < 0.05).
VOL. 76 (1), 23-44, 2010          BETA-CELL HYPERPLASIA INDUCED BY HEPATIC INSULIN...
39
insulin signaling and that the severity of this resistance depends on the
level of IR deletion; iLIRKO mice suffer early insulin resistance, as a
primary defect, directly related to the ablation of IR, but also have
impaired insulin signaling in extra hepatic tissues. Thus, iLIRKO mice
induce late insulin resistance, as a secondary effect. Given the fact that
IR expression in those tissues was not affected, this effect may be
likely due to IR desensitisation due to prolonged hyperinsulinemia.
Our results demonstrate that a primary defect in the liver triggers a
secondary insulin resistance in extra hepatic tissues. Accordingly, the
progression to diabetes only requires defects in the liver as observed
in iLIRKO mice.
Insulin resistance is associated with hyperinsulinemia and leads
to beta-cell hyperplasia. Thus, early IR deletion by the liver in
constitutive LIRKO induced beta-cell hyperplasia (8). However,
in mice in which was created muscle-specific insulin resistance
by conditional inactivation of the IR (MIRKO mice, 11), no islet
hyperplasia was found in response to the isolated muscle insulin
resistance. More importantly, insulin levels are elevated in most states
of insulin resistance, including the LIRKO mouse, but are not elevated
in MIRKO mouse. Our results with iLIRKO demonstrate a direct
relationship between the level of IR deletion by the liver and the fold-
increase of plasma insulin levels and also beta-cell mass. Finally,
constitutive LIRKO developed hypersecretion of insulin for more than
one year. However, in iLIRKO mice compensatory hyperinsulinemia
in 1 year-old mice was much lower than in 6 month-old mice. Thus,
a failure in the beta cells insulin secretion seems to occur, given the
fact of the inhibition of the insulin clearance by the liver, the major
site of insulin degradation in an IR-dependent manner (25). More
importantly, iLIRKO suggests that owing to severe insulin resistance
and prolonged hypersecretion of insulin, the beta cells ultimately
undergo a failure in insulin secretion.
Previous evidence demonstrated that insulin signaling is essential
for beta-cell growth (10, 26). Just recently, IR double null allele in
the liver and in the beta cells failed to induce beta-cell hyperplasia
in response to severe insulin resistance. In fact, the persistence of
robust hyperplasia in six month-old hypoglycemic LIRKO mice
supports the concept of a glucose-independent circulating islet
growth factor (27). In this context, iLIRKO mice induced IGF-1
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expression in parallel to IR deletion in the liver. This resulted in a
persistent increase of plasma IGF-1, consistent with the fact that the
liver is the main source of circulating IGF-1 (28). Previous data
demonstrated that IGF-1R in the beta-cell is not crucial for islet
β-cell mass growth, but participates in control of differentiated
function (29). In fact, we have found a relationship among beta-cell
hyperplasia, hyperinsulinemia and an increase of genes related to
beta-cell proliferation and differentiation in iLIRKO mice. Thus, IGF-
1 signaling might be involved in the induction of genes related to
glucose-stimulated insulin secretion among others. However, IGFBPs
regulates the IGF-1 systemic effect in a complex manner (30). More
importantly, iLIRKO mice induced IGFBP1 in parallel to IGF-1
depending on the level of IR deletion by the liver. These results are
entirely consistent with the insulin-mediated effect on the IGFBP1
gene expression by the liver cells (31). IGFBP1, which is mainly
produced by the liver in the adult mice, inhibits IGF-dependent
cellular growth in vivo (30, 32, 33). In addition, adult transgenic
mice showed glucose intolerance and fasting hyperglycemia and
hyperinsulinemia. However, the hyperinsulinemia observed in
IGFBP1 transgenic mice can not be attributable to insulin resistance
alone (34, 35). In fact, adult transgenic mice showed larger and more
numerous beta-cell islets and also an increased beta-cell proliferation
(36). Finally, iLIRKO mice showed an increase in the IR expression
in the pancreatic islets. More importantly, an increase in the
proportion of IR-A versus IR-B in the total percentage of IR was
observed in pancreatic islets from iLIRKO mice. On this regard, it
was previously reported that IGF-2 and also IGF-1 showed a high
affinity to IR-A (37). In addition, BrdU incorporation experiments
performed in pancreatic islets isolated from 6-month-old control and
iLIRKO mice revealed that the islets from iLIRKO mice were
significantly more sensitive to the IGF-1-induced proliferation.
Moreover, as assessed in mouse beta-cell lines, occurrence mostly of
IR-A in pancreatic islets from iLIRKO mice might imply firstly, an
increase in the rate of glucose uptake, a mitogenic signal in beta
cells independently of insulin (17) and secondly, an enhanced
proliferation in response to either insulin or IGF-1. Taking together,
IR-A, but not IR-B, confers a proliferative capability to beta-cells in
response to insulin or IGF-1 that may account for beta-cell
hyperplasia induced by liver insulin resistance in iLIRKO mice.
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In conclusion, our results showed that a defect in the liver leads
to an overall insulin resistance. Given the fact that insulin resistance
states course with compensatory beta-cell hyperplasia, iLIRKO
studies have pointed out a cause and effect relationship between
progressive insulin resistance and beta-cell hyperplasia. Ultimately,
the beta cells could undergo a failure in the insulin secretion that
leads to uncontrolled diabetes. Thus, in these mice, isolated hepatic
insulin resistance is sufficient to recapitulate the progressive
pathogenesis of type 2 diabetes. In this context, iLIRKO mice
induced IGF-1 expression in parallel to IR deletion in the liver. This
resulted in a persistent increase of circulating IGF-1. Concurrently,
there was a huge increase of IR-A in the total percentage of IR in the
hyperplastic pancreatic islets from iLIRKO mice. Thus, our results
in iLIRKO mice suggest a liver-pancreatic endocrine axis, IGF-1
being a liver factor that might contribute to compensatory beta-cell
hyperplasia through IR-A.
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